Brainstorm Cell Therapeutics Inc
XBER:GHDN
Brainstorm Cell Therapeutics Inc
XBER:GHDN
Price:
3.255
EUR
Market Cap:
€1.2B
Relative Value
There is not enough data to reliably calculate the relative value of GHDN.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
GHDN
Relative Value
Base Case
Not Available
Multiples Across Competitors
GHDN Competitors Multiples
Brainstorm Cell Therapeutics Inc Competitors
Brainstorm Cell Therapeutics Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
|
Brainstorm Cell Therapeutics Inc
XBER:GHDN
|
9.9m EUR | 0 | -0.8 | -0.7 | -0.7 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 690 872.8 | -160 127.7 | -194 446.1 | -192 227.3 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
388.5B USD | 6.1 | 89.7 | 14.9 | 20.6 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
194.6B USD | 5.2 | 24.8 | 14.3 | 14.3 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
179.2B USD | 6 | 20.7 | 12.9 | 15.9 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
117.5B USD | 9.6 | 29.3 | 22 | 23 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 091 | -533.6 | -581 | -565.5 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
80.2B USD | 5.4 | 17.3 | 12.7 | 14.5 | |
| AU |
|
CSL Ltd
ASX:CSL
|
67.1B AUD | 3.1 | 34.1 | 11.3 | 14.2 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.1 | -61.8 | -66.6 | -60.1 | |
| NL |
|
argenx SE
XBRU:ARGX
|
37.5B EUR | 10.6 | 34 | 36.8 | 37.6 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
